Trial Profile

A Ib clinical study for the neoadjuvant use of PH-762 administered by intratumoral injection in patients with advanced resectable melanoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 29 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PH 762 TME (Primary)
Indications Malignant melanoma
Focus Adverse reactions; First in man
Sponsors Phio Pharmaceuticals

Most Recent Events

06 Oct 2022 According to a Phio Pharmaceuticals media release, data from this trial will be presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
07 Jun 2022 Trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology
06 Jun 2022 According to a Phio Pharmaceuticals media release, a trial-in-progress poster describing the study outline of Phase 1b clinical trial of PH-762, has been presented at the 2022 American Society of Clinical Oncology (ASCO) annual meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com